

# African Vaccine manufacturing Initiative (AVMI), Vaccine Production in Ethiopia

---

Southern Sun Hotel, Cape Town

Birhanu Hurisa  
Ethiopian Public Health Institute  
Nov. 30, 2016  
[www.ephi.gov.et](http://www.ephi.gov.et)



# History



30 octobre 1954 :  
Haile Selassie,  
empereur  
d'Éthiopie,  
Jacques Trefouël,  
directeur de  
l'Institut Pasteur  
et Louis Pasteur  
Vallery-Radot

2014

Used to produce anti-rabies, Small Pox, anti-typhoid-paratyphoid, Cholera and B.C.G vaccines.

NVI emerged from  
EPHI

Background history  
support us

- ❖ For more than five decades EPHI is producing and distributing NTV
- ❖ >32,000 of vials of NTV is distributed to the nation annually



# In pipe line cell-culture based anti-rabies



# Achievements

- ❖ Fully transferred the technology for animal vaccine production





TT  
Ceremony



Training of NVI staff

# Progress

- ❖ Currently focused cell culture based rabies vaccine production for human use
- ❖ Technical support from CDC, Atlanta
- ❖ Closely working with regulatory agency
- ❖ Pilot production started in October
- ❖ Purification will be planned to done in December (Ultracentrifuge installation)
- ❖ Clinical trial is planned to carried out in 2016/17

# Plan

- Rabies monoclonal antibody
  - ❖ Polyvalent anti-venom from poisonous snakes
  - ❖ Poly. Meningitis
  - ❖ Cholera vaccine
  - ❖ Anti-typhoid
  - ❖ Yellow fever vaccine
- 
- Major equipment were procured

# Challenges

- ❖ high cost for vaccine development and infrastructure
- ❖ Lack of partnership
- ❖ High standards of GMP
- ❖ Very stringent regulation system
- ❖ Lack of skilled staff and high attrition

# Opportunity

❖ Commitment of the Government

**THANK YOU**